Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Blood (2016) 128 (22): 470.

https://doi.org/10.1182/blood.V128.22.470.470

Published: 2016

Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD

Blood (2016) 128 (22): 6.

https://doi.org/10.1182/blood.V128.22.6.6

Published: 2016

Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Blood (2015) 126 (23): 496.

https://doi.org/10.1182/blood.V126.23.496.496

Published: 2015

Journal Articles

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Dan Lu, Jin Yan Jin, Leonid Gibiansky, William R. Gillespie, Priya Agarwal, Cheryl Jones, Yu-Waye Chu, Michael K. Wenger, Jamie Hirata, Chunze Li, Sandhya Girish

Blood (2015) 126 (23): 1525.

https://doi.org/10.1182/blood.V126.23.1525.1525

Published: 2015

Journal Articles

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

Valentin Goede, MD, Anja Engelke, MD, Kirsten Fischer, Javier Lopez Jimenez, Alexej Kuzmin, Martin JS Dyer, Katell Le Dû, Anna Marina Liberati, Rudolf Schlag, Anton W Langerak, Matthias Ritgen, Stephan Stilgenbauer, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, Günter Fingerle-Rowson, Michael Hallek, MD

Blood (2014) 124 (21): 3327.

https://doi.org/10.1182/blood.V124.21.3327.3327

Published: 2014

Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Blood (2014) 124 (3): 420–425.

https://doi.org/10.1182/blood-2013-12-538975

Published: 2014

Includes: Supplemental data

Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Blood (2014) 123 (21): 3247–3254.

https://doi.org/10.1182/blood-2014-01-546150

Published: 2014

Includes: Supplemental data

Journal Articles

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Andrew Davies, MRCP, PhD, John Radford, MD, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, MD, PhD, Robert Marcus, MB, FRCP, FRCPath, Michael K Wenger, MD, Guiyuan Lei, PhD, Elisabeth Wassner-Fritsch, PharmD, Umberto Vitolo, MD

Blood (2013) 122 (21): 1814.

https://doi.org/10.1182/blood.V122.21.1814.1814

Published: 2013

Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 671.

https://doi.org/10.1182/blood.V122.21.671.671

Published: 2013

Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Blood (2013) 122 (21): 6.

https://doi.org/10.1182/blood.V122.21.6.6

Published: 2013

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

John Radford, MD, Andrew Davies, Guillaume Cartron, MD, PhD, Franck Morschhauser, MD, PhD, Gilles Andre Salles, Robert E. Marcus, MBBS, FRCP, FRCPath, Michael K. Wenger, Elina Asikanius, Elisabeth Wassner-Fritsch, Umberto Vitolo, MD

Blood (2011) 118 (21): 270.

https://doi.org/10.1182/blood.V118.21.270.270

Published: 2011

Journal Articles

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Dirk Winkler, MD, Raymonde Busch, Andreas Buehler, MD, Michael K. Wenger, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2011) 118 (21): 2841.

https://doi.org/10.1182/blood.V118.21.2841.2841

Published: 2011

Journal Articles

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Anna Fink, MD, Raymonde Busch, Natali Pflug, MD, Sebastian Boettcher, MD, Dirk Winkler, MD, Andreas Buehler, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Myriam Mendila, MD, Michael K. Wenger, MD, Hartmut Doehner, MD, Michael Kneba, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2011) 118 (21): 977.

https://doi.org/10.1182/blood.V118.21.977.977

Published: 2011

Journal Articles

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Gilles Andre Salles, Franck Morschhauser, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Thierry Lamy, MD, PhD, Herve Tilly, Pierre Feugier, MD, PhD, Steven Le Gouill, MD, PhD, Emmanuel Gyan, MD, PhD, Reda Bouabdallah, MD, Michael K. Wenger, MD, Elisabeth Wassner-Fritsch, Elina Asikanius, Guillaume Cartron, MD, PhD

Blood (2011) 118 (21): 268.

https://doi.org/10.1182/blood.V118.21.268.268

Published: 2011

Journal Articles

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Franck Morschhauser, MD, PhD, Guillaume Cartron, MD, PhD, Catherine Thieblemont, MD, Philippe Solal-Celigny, Corinne Haioun, MD, Reda Bouabdallah, MD, Thierry Lamy, MD, PhD, Noel Milpied, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, PhD, Michael K. Wenger, Elisabeth Wassner-Fritsch, Elina Asikanius, Gilles Andre Salles

Blood (2011) 118 (21): 3655.

https://doi.org/10.1182/blood.V118.21.3655.3655

Published: 2011

Journal Articles

Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),

David Carlile, PhD, Georgina Meneses-Lorente, PhD, Elisabeth Wassner-Fritsch, Florence Hourcade-Potelleret, PhD, Michael K. Wenger, Guillaume Cartron, MD, PhD, Umberto Vitolo, MD, John Radford, MD, Andrew Davies, Franck Morschhauser, MD, PhD

Blood (2011) 118 (21): 3704.

https://doi.org/10.1182/blood.V118.21.3704.3704

Published: 2011

Journal Articles

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Sebastian Boettcher, MD, Matthias Ritgen, MD, Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Gunter R. Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Andreas Buehler, MD, Dirk Winkler, MD, Michael K. Wenger, MD, Myriam Mendila, MD, Clemens Wendtner, MD, Barbara Eichhorst, MD, Hartmut Döhner, MD, Michael Hallek, MD, Michael Kneba, MD

Blood (2011) 118 (21): 1777.

https://doi.org/10.1182/blood.V118.21.1777.1777

Published: 2011

Journal Articles

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Michinori Ogura, MD, PhD, Franck Morschhauser, MD, PhD, Kensei Tobinai, MD, PhD, Guillaume Cartron, MD, PhD, Kiyohiko Hatake, MD, PhD, Michael K. Wenger, MD, Joe Birkett, PhD, Naoko Oya, Kiyomi Nishima, Gilles Salles, MD, PhD

Blood (2010) 116 (21): 4921.

https://doi.org/10.1182/blood.V116.21.4921.4921

Published: 2010

NARROW

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma

Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000)

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000)

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999)

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Comparison of Single Agent GA101 In Japanese and European Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) – Results From Two Phase I Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only